Company Information
- CEO
- Dr. Andreas Wicki
- Investor Relations
- n/a
HBM BioVentures invests globally in the human medicine / biotechnology and medical technology sectors. As a venture capital company it manages a mature, widely diversified portfolio of private and emerging small-cap public companies.
Trading Information
- Sector
- Financial Services (incl. Real Estate) - 8700
- Regulatory Standard
- Standard for Investment Companies
- Security Number
- 1262725
- ISIN
- CH0012627250
- Symbol
- HBMN
- Index member
- SXI Life Sciences/SXI Bio+Medtech
Intermediaries
- Listing Agent
- UBS Investment Bank
- Lead Bank
- UBS Investment Bank
- Auditor
- Ernst & Young Ltd.
Information on the Issue
| Security Details | |
|---|---|
| First Listing | 14.02.2008 |
| Class of Share | Action nominative |
| Nominal Value | 60.00 CHF |
| Total Shares outstanding (post issue; incl. Greenshore - if any) | 11262859 |
| Allocation Details | |
|---|---|
| Primary Shares | n/a |
| Secondary Shares | n/a |
| Primary Greenshoe | n/a |
| Secondary Greenshoe | n/a |
| Greenshoe Details | |
|---|---|
| Executed | no GS at all |
| Ex-date | n/a |
| Executed number of shares | n/a |
| First Trading Day Details | |
|---|---|
| First Trading | 14.02.2008 |
| Price Range | n/a |
| Issue Price | n/a |
| First Open | 80.50 CHF |
| First Close | 82.00 CHF |
| Transaction size in Mio. (incl. executed Greenshoe) | n/a |
| Market Capitalisation in Mio. (based on first closing price) | 924 CHF |
Financial Statement
| Number of Employees | 4 |
| Net Revenues in Mio. | n.a. CHF |
| Net Gain in Mio. | n/a |